Form 4: Immuneering Corp CEO Benjamin J. Zeskind Acquires 20,000 Shares
SEC Form 4 Filing
Immuneering Corp's CEO, Benjamin J. Zeskind, purchased 20,000 shares of Class A Common Stock at an average price of $2.7663 on March 19, 2024.
Summary
- On March 19, 2024, Benjamin J. Zeskind, the President and CEO of Immuneering Corp, acquired 20,000 shares of Class A Common Stock.
- The shares were purchased at a weighted average price of $2.7663, with individual trades ranging from $2.54 to $2.95.
- Following this transaction, Mr. Zeskind directly owns 2,281,852 shares of Class A Common Stock.
- Additionally, 894,927 shares are held indirectly through the Benjamin J. Zeskind 2020 Family Trust, for which his spouse, Lisa Schwartz, serves as the sole trustee.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a transaction. The CEO buying shares is generally a positive sign, but without additional context, it's difficult to gauge the overall impact.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.
Stakeholder Impact
- Shareholders may view the CEO's purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 03/19/2024 | Date of the transaction where Benjamin J. Zeskind acquired 20,000 shares of Class A Common Stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.